Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 726951

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

Von Minckwitz, G.; Puglisi, F.; Cortes, J.; Vrdoljak, Eduard; Marschner, N.; Zielinski, C.; Villanueva, C.; Romieu, G.; Lang, I.; Ciruelos, E. et al.
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. // Lancet oncology, 15 (2014), 11; 1269-1278 doi:10.1016/S1470-2045(14)70439-5 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 726951 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

Autori
Von Minckwitz, G. ; Puglisi, F. ; Cortes, J. ; Vrdoljak, Eduard ; Marschner, N. ; Zielinski, C. ; Villanueva, C. ; Romieu, G. ; Lang, I. ; Ciruelos, E. ; De Laurentiis, M. ; Veyret, C. ; de Ducla, S. ; Freudensprung, U. ; Srock, S. ; Gligorov, J.

Izvornik
Lancet oncology (1470-2045) 15 (2014), 11; 1269-1278

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
metastatic breast cancer

Sažetak
Combining bevacizumab with first-line or second-line chemotherapy improves progression- free survival in HER2-negative locally recurrent or metastatic breast cancer. We assessed the efficacy and safety of further bevacizumab therapy in patients with locally recurrent or metastatic breast cancer whose disease had progressed after treatment with bevacizumab plus chemotherapy.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
Medicinski fakultet, Split

Profili:

Avatar Url Eduard Vrdoljak (autor)

Poveznice na cjeloviti tekst rada:

doi www.thelancet.com dx.doi.org

Citiraj ovu publikaciju:

Von Minckwitz, G.; Puglisi, F.; Cortes, J.; Vrdoljak, Eduard; Marschner, N.; Zielinski, C.; Villanueva, C.; Romieu, G.; Lang, I.; Ciruelos, E. et al.
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. // Lancet oncology, 15 (2014), 11; 1269-1278 doi:10.1016/S1470-2045(14)70439-5 (međunarodna recenzija, članak, znanstveni)
Von Minckwitz, G., Puglisi, F., Cortes, J., Vrdoljak, E., Marschner, N., Zielinski, C., Villanueva, C., Romieu, G., Lang, I. & Ciruelos, E. (2014) Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.. Lancet oncology, 15 (11), 1269-1278 doi:10.1016/S1470-2045(14)70439-5.
@article{article, author = {Von Minckwitz, G. and Puglisi, F. and Cortes, J. and Vrdoljak, Eduard and Marschner, N. and Zielinski, C. and Villanueva, C. and Romieu, G. and Lang, I. and Ciruelos, E. and De Laurentiis, M. and Veyret, C. and de Ducla, S. and Freudensprung, U. and Srock, S. and Gligorov, J.}, year = {2014}, pages = {1269-1278}, DOI = {10.1016/S1470-2045(14)70439-5}, keywords = {metastatic breast cancer}, journal = {Lancet oncology}, doi = {10.1016/S1470-2045(14)70439-5}, volume = {15}, number = {11}, issn = {1470-2045}, title = {Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.}, keyword = {metastatic breast cancer} }
@article{article, author = {Von Minckwitz, G. and Puglisi, F. and Cortes, J. and Vrdoljak, Eduard and Marschner, N. and Zielinski, C. and Villanueva, C. and Romieu, G. and Lang, I. and Ciruelos, E. and De Laurentiis, M. and Veyret, C. and de Ducla, S. and Freudensprung, U. and Srock, S. and Gligorov, J.}, year = {2014}, pages = {1269-1278}, DOI = {10.1016/S1470-2045(14)70439-5}, keywords = {metastatic breast cancer}, journal = {Lancet oncology}, doi = {10.1016/S1470-2045(14)70439-5}, volume = {15}, number = {11}, issn = {1470-2045}, title = {Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.}, keyword = {metastatic breast cancer} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.